Syros Pharmaceuticals (SYRS) Earnings Date, Estimates & Call Transcripts $0.01 0.00 (-0.99%) As of 07/18/2025 03:54 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Syros Pharmaceuticals Earnings Summary Syros Pharmaceuticals announced Q3 2024 earnings on October 31, 2024, reporting an EPS of -$0.68, which beat the consensus estimate of -$0.76 by $0.08. With a trailing EPS of -$3.03, Syros Pharmaceuticals' earnings are expected to decrease next year, from ($2.94) to ($2.97) per share. Upcoming Q4 Earnings DateJul. 29Before Market OpensEstimatedConsensus EPS (Oct. 31) -$0.76 Actual EPS (Oct. 31) -$0.68 Beat By $0.08 Q3 2024 Earnings ResourcesQ3 2024 Earnings ReportConference Call Transcript & Audio Quarterly Report (10-Q)SYRS Upcoming EarningsSyros Pharmaceuticals' next earnings date is estimated for Tuesday, July 29, 2025, based on past reporting schedules. Powered by Get Syros Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Syros Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSYRS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SYRS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Syros Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.70-$0.70-$0.70Q2 20251-$0.72-$0.72-$0.72Q3 20251-$0.68-$0.68-$0.68Q4 20251-$0.69-$0.69-$0.69 Syros Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 7/29/2025(Estimated)--------10/31/2024Q3 2024-$0.76-$0.68+$0.08-$1.20--7/31/2024Q2 2024-$0.79-$0.70+$0.09-$0.81--5/14/2024Q1 2024-$0.89-$0.79+$0.10-$1.48$1.30M-3/27/2024Q4 2023-$1.23-$1.19+$0.04-$0.20$2.40M$0.39M11/14/2023Q3 2023-$1.12-$1.35 -$0.23-$1.27$3.90M$3.76M8/8/2023Q2 2023-$1.11-$1.30 -$0.19-$1.30$3.17M$2.83M Syros Pharmaceuticals Earnings - Frequently Asked Questions When is Syros Pharmaceuticals' earnings date? Syros Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, July 29th, 2025 based off last year's report dates. Learn more on SYRS's earnings history. Did Syros Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Syros Pharmaceuticals (NASDAQ:SYRS) reported ($0.68) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.76) by $0.08. Learn more on analysts' earnings estimate vs. SYRS's actual earnings. How can I listen to Syros Pharmaceuticals' earnings conference call? The conference call for Syros Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read Syros Pharmaceuticals' conference call transcript? The conference call transcript for Syros Pharmaceuticals' latest earnings report can be read online. Read Transcript How much revenue does Syros Pharmaceuticals generate each year? Syros Pharmaceuticals (NASDAQ:SYRS) has a recorded annual revenue of $386,000.00. How much profit does Syros Pharmaceuticals generate each year? Syros Pharmaceuticals (NASDAQ:SYRS) has a recorded net income of -$164.57 million. SYRS has generated -$3.03 earnings per share over the last four quarters. What is Syros Pharmaceuticals' EPS forecast for next year? Syros Pharmaceuticals' earnings are expected to decrease from ($2.94) per share to ($2.97) per share in the next year. More Earnings Resources from MarketBeat Related Companies SXTP Earnings UBX Earnings PBM Earnings AFMD Earnings WINT Earnings PRFX Earnings ZVSA Earnings ONCO Earnings PCSA Earnings ALZN Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report This page (NASDAQ:SYRS) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersTurn $1K into $50K with This DeFi GemTHREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
